Shlomo Wiesen

The field of genetic and cellular medicines is advancing at an unprecedented pace, and there

Managing the lifecycle of Investigational Medicinal Products (IMP) requires more than just logistics; it demands

In the modern drug development world, the transition from clinical phases to commercial viability is

The pharmaceutical landscape is shifting beneath our feet. As the industry prepares for DCAT Week

As we look toward the 2026 regulatory horizon, the European landscape is undergoing its most

The intersection of Artificial Intelligence and drug development reached a fever pitch on January 14,

The FDA’s January 2026 announcement on “Flexible Requirements for Cell and Gene Therapies” has sent